Last updated on October 2018

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

Brief description of study

SHRINK (Standard cHemotherapy Regimen and Immunotherapy with NKR-2) is an open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells administered concurrently with a standard chemotherapy treatment (FOLFOX) in potentially resectable liver metastases from colorectal cancer.

The trial will test three dose levels. At each dose, the patients will receive three successive administrations, two weeks apart, NKR-2 cells. The study will enroll up to 36 patients (dose escalation and expansion phases).

Clinical Study Identifier: NCT03310008

Contact Investigators or Research Sites near you

Start Over

Alain Hendlisz, MD

Institut Jules Bordet
Brussels, Belgium
  Connect »

Jean-Pascal Machiels, MD

Cliniques universitaires Saint-Luc
Brussels, Belgium
  Connect »

Jean-Luc Canon, MD

Grand H pital de Charleroi
Charleroi, Belgium
  Connect »

Eric Van Cutsem, MD

UZ Leuven
Leuven, Belgium
  Connect »